FDA approves Quantel Medical's 577 nm photocoagulator laser for ophthalmic use

July 31, 2017

The Easyret 577 nm photocoagulator laser is used to treat certain forms of macular edema and peripheral retinal pathologies.

On July 25, 2017, Quantel Medical (Cournon-d'Auvergne, France) received approval from the U.S. FDA for its Easyret 577 nm photocoagulator laser, which is used to treat certain forms of macular edema and peripheral retinal pathologies.

In 2016, the company introduced fiber laser technology for 577 nm yellow lasers in Europe. This technical breakthrough is based on the company's ELBA fiber laser technology, which the company has utilized in scientific and industrial areas.

"The Easyret's ELBA fiber laser cavity delivers pure 577 nm yellow wavelength in a uniform top-hat laser spot profile, making it ideal for ophthalmic applications," explains Jean-Marc Gendre, CEO of Quantel Medical. "Quantel engineers worked closely with surgeons to design a fully integrated system with an intuitive interface to ensure optimal ergonomics and ease of use," Gendre adds.

The Easyret has a broad range of settings for treatment of pathologies such as diabetic retinopathy, macular edema, and central serous chorioretinopathy. In addition to SingleSpot treatment mode, surgeons can select Multispot mode for a pattern of simultaneous targets or the SubLiminal mode, which enables them to customize a train of short pulses to precisely manage thermal effect on targeted tissues.

For more information, please visit www.quantel-medical.com.